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demand in research and clinical applications. Their current pu-
riﬁcation processes represent the main bottleneck in their
widespread use, as the methods used are cumbersome and yield
low recoveries. We aimed to develop a one-step method to
speciﬁcally purify LVs, with high yields and reduced levels of
impurities, using the biotin-streptavidin system. Herein, pack-
aging HEK293T cells were genetically engineered with a cyclical
biotin-mimicking peptide displayed on a CD8a stalk, termed
cTag8. LVs were modiﬁed with cTag8 by its passive incorpora-
tion onto viral surfaces during budding, without viral protein
engineering or hindrance on infectivity. Expression of cTag8
on LVs allowed complete capture of infectious particles by
streptavidin magnetic beads. As cTag8 binds streptavidin in
the nanomolar range, the addition of micromolar concentra-
tions of biotin resulted in the release of captured LVs by
competitive elution, with overall yields of R60%. Analysis of
eluted LVs revealed high purity with a >3-log and 2-log reduc-
tion in DNA contamination and host cell proteins, respectively.
This one-step puriﬁcation was also tested for scalable vector
processing using monolith afﬁnity chromatography, with an
encouraging preliminary overall yield of 20%. This method
will be of valuable use for both research and clinical applica-
tions of LVs.Received 12 April 2018; accepted 17 October 2018;
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Over the past decade, lentiviral vectors (LVs) have become increas-
ingly utilized in clinical gene therapy with a concomitant increased
need for large-scale high speciﬁcation manufacture. A major obstacle
in LV manufacturing is the lack of commercially viable, robust, and
scalable downstream processing that is compliant with good
manufacturing practice (GMP) standards and results in high recovery
and purity of ﬁnal vector product. Here, we explore a single-step af-
ﬁnity-column viral puriﬁcation method that yields high recovery with
reduced levels of impurities.
Current large-scale processing schemes of LVs use multiple processes
to capture viral particles, eliminate contaminants, and polish vectorMolecular Therapy: Methods & Clin
This is an open access article under tproducts.1,2 Post-clariﬁcation, concentration is commonly achieved
by ultraﬁltration (UF)/diaﬁltration (DF) of the LV product, with
tangential ﬂow ﬁltration being the most commonly used process.3–6
Puriﬁcation is then usually achieved by chromatographic means,
with anion exchange chromatography (AEX) being the most
commonly used in both research and clinical-grade LV applica-
tions.7–12 As AEX results in the co-puriﬁcation of nucleic acids, which
currently represents the major contaminant of LV supernatant,13
most large-scale downstream processing schemes also include a
nuclease treatment step using Benzonase, which in turn needs to be
removed from the ﬁnal product.5,14–17 Size exclusion chromatog-
raphy (SEC), which suffers from product dilution and slow ﬂow rates,
is then used as a polishing step.18
The expression of a peptide tag on the surface of viral particles
would enable the selective capture of vector particles by afﬁnity
chromatographic puriﬁcation. Unlike most methods currently
used, the high speciﬁcity of afﬁnity-based puriﬁcation should
enable the selective capture of target vectors from virus-containing
medium, which provides an increased product yield, reduce the
number of steps required for puriﬁcation and in turn reduce the
cost of manufacturing. The expression of a tag on viral particles
has typically been achieved by engineering viral envelope glycopro-
teins, often at the cost of loss of particle infectivity.19–24 A few
studies have reported the afﬁnity puriﬁcation of engineered LVs
using ligands such as hexahistidine.25,26 However desorption of
vectors from captured columns required the use of imidazole,
which has been shown to cause LV inactivation.18,24 Therefore,
although afﬁnity chromatography is an attractive concept for LV
puriﬁcation, its main challenge remains the lack of a means forical Development Vol. 11 December 2018 ª 2018 The Authors. 155
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Molecular Therapy: Methods & Clinical Developmentgentle desorption of vectors to minimize vector inactivation and
retain maximum levels of infectivity.
Among the different afﬁnity-based puriﬁcations, the biotin-(strept)
avidin system, with its high afﬁnity (dissociation constant, KD,
1015 M),27 is one of the most utilized. The strength of this interac-
tion however hinders the desorption and recycling of streptavidin
matrices. Peptides, termed “biotin mimics” that bind streptavidin
have been described. These have two advantages: ﬁrst, they can be
genetically encoded; and second, they bind streptavidin with a lower
afﬁnity potentially allowing the release of captured targets with biotin.
Several linear streptavidin-binding peptides now exist, with afﬁnities
ranging from micromolar28–32 to nanomolar,33–35 and are used in
various applications for research and commercial purposes. There
is reason to suggest however that other structural conformations,
such as cyclical biotin mimics, might be superior to linear peptides
in terms of stable binding conﬁrmation36 and increased ligand
afﬁnity.37,38
Here, we expressed cyclical biotin mimetope on the surface of LV
packaging cells as a type I transmembrane protein. We showed that
the surface expressingmimic was passively incorporated onto LV par-
ticles during virion budding without loss of titer. This allowed LV
particles to be captured on streptavidin. We then exploited the lower
afﬁnity for streptavidin of the mimetope than biotin to competitively
release viral particles in physiological conditions. This system was
explored as an LV puriﬁcation strategy.
RESULTS
Comparison of Three Biotin Mimics for Streptavidin Binding on
Different Structural Formats
We ﬁrst sought to determine an optimal cell-membrane-expressed,
genetically encodable, biotin-mimicking protein. Such a protein
requires the biotin mimic to be fused to a membrane-bound spacer
domain. We compared three biotin mimetopes: the linear peptide
Streptag-II, (which binds streptavidin with afﬁnity 13 mM)32 and
two variants of a cyclical peptide, short cTag (s-cTag) and ﬂanked
cTag (CHPQGPPC and ECHPQGPPCIEGRK, respectively, which
bind streptavidin at 230 nM).39 These mimics were fused either
directly to the stalk-transmembrane domain of CD8a or to a gly-
cosylphosphatidylinositol (GPI) anchor. Preliminary data indi-
cated poor accessibility to the GPI anchor, so a second variant
was made with two copies of each mimic (Figure 1A). Fusion pro-
teins were co-expressed with EGFP and transfected into 293T cells,
and streptavidin allophycocyanin (APC) binding was normalized
to EGFP. Flanked cTag bound streptavidin with the highest me-
dian ﬂuorescence intensity (MedFI) (14,956 ± 1,668), compared
to short cTag (10,043 ± 185) and Streptag-II (8,049 ± 1,064) on
CD8a stalks (Figure 1B). Both GPI variants for all mimics resulted
in signiﬁcantly lower MedFIs (between 3,440 ± 225 and 10,804 ±
1,204), compared to the CD8a variants (Figure 1B). As the objec-
tive was high surface expression level, the construct of the ﬂanked
cTag on a CD8a stalk, termed cTag8, was selected for further
study. To further validate cTag8 as a biotin mimic, its reversible156 Molecular Therapy: Methods & Clinical Development Vol. 11 Decembinding to streptavidin was demonstrated by biotin’s competitive
binding (Figure 1C).
Establishment of cTag8-Modified Vector Packaging Cells
Having shown that the mimetic protein could bind soluble strepta-
vidin, we next sought to show that it could also bind matrix-bound
streptavidin. A K562 cell line was engineered to stably express cTag8
using the same EGFP-fused construct as before, and their selection
was demonstrated with streptavidin-coated paramagnetic beads
(Figures S1A and S1B). With this proof of principle established, a
293T cell line stably expressing cTag8 was generated (Figures 2A
and 2B) for use as a host cell line for virus production. The impact
of the expression cTag8 on the ability of the 293T cell to produce
LVs and any impact on subsequent lentiviral particles was then
investigated. Non-modiﬁed (NM) LVs and cTag8 LVs were tran-
siently produced from 293T and cTag8 293T cells, respectively,
and transfected with a second-generation lentiviral packaging sys-
tem using three different pseudotyping envelopes: RDpro,40 MLV-
ampho, and vesicular stomatitis virus G protein (VSV-G). Viral
titers were determined by infectious assay (Figure 2C). Expression
of cTag8 had no effect on titer. In addition, transmission electron
microscopy (TEM) of VSV-G pseudotyped NM LVs and cTag8
LVs showed no morphological differences between the virions
(Figure 2D).
Complete Capture of cTag8-Modified LVs by Passive
Incorporation in Serum-free Medium
We next sought to determine whether viral particles produced from
cTag8 293T cells could be captured on a streptavidin matrix. Since
free biotin in the culture media might compete for streptavidin,
consideration was given to culture media: Iscove’s modiﬁed Dulbec-
co’s medium (IMDM) contains 52.3 nM biotin, while DMEM con-
tains none. Further, fetal calf serum (FCS) typically contains 2 nM
biotin.41 Hence, 293T cells or cTag8 293T cells were cultured in
either FCS-supplemented IMDM (serum) or in serum-free
DMEM (plain) 24 hr after transfection with lentiviral plasmids.
Harvested supernatants were 0.45 mM ﬁltered and incubated with
streptavidin Dynabeads at 0.5 mg beads per milliliter of LV superna-
tants for 2 hr at 4C, with gentle rotation. Magnetic beads were then
magnetically immobilized and “ﬂow-through” fractions were
collected. Filtered, but otherwise unmanipulated, supernatant
(“neat” supernatant) was also kept as a control. Viral titers of
neat, ﬂow-through, and bead fractions were determined by infec-
tious assays of 293T cells (Figure 3A). The bead fractions of both
serum and plain-capture conditions resulted in no signiﬁcant differ-
ence to their neat respective fractions, with 0.9 ± 0.046 and 0.91 ±
0.098 of the total viral input captured by streptavidin from cTag8
293T cells. In contrast (and as expected), no bead capture was
observed with 293T cell supernatant. Further, 0.21 ± 0.021 of the
cTag8 LV vector was found in the ﬂow-through fraction in the pres-
ence of IMDM and FCS, while none was found if plain DMEM was
used. Lastly, cTag8 LVs bound streptavidin in a stable manner
throughout the capture process, as no infectious particles were de-
tected in the wash fractions post-capture (Figure S2).ber 2018
Figure 1. Reversible Streptavidin Binding of Synthetic Surface Expressing Biotin Mimics
(A) Schematic diagrams of the chosen mimics with their reported dissociation constants (KD). Four surface expression structures were cloned, and their architectures are
represented: (1) Flush, consisting of a CD8-derived transmembrane (TM) and endodomain (Endo); (2) GPI, consisting of GPI anchor sequence (25 amino acids [aa]), which
leads to the addition of GPI at the anchor sequence, with a serine-glycine linker (6 aa); (3) x2-GPI, consisting of 2 copies of the epitopes’ open reading frame (ORF) separated
by a serine-glycine linker with the first 14 aa of the CD8a stalk ectodomain (Ecto; Linker_CD8), on a GPI anchor sequence; (4) CD8a, consisting of the CD8a stalk comprising
the ecto-, transmembrane, and endodomains of the human CD8a molecule, with a serine-glycine linker. All peptides were cloned into a retroviral plasmid termed “SFG,”
derived from the Moloney murine leukemia virus (MoMLV), upstream of the EGFP marker gene expressed by an internal ribosome entry site (IRES). (B) 293T cells were
transiently transfected with all cloned constructs and stained with APC-conjugated streptavidin 48 hr later. The median fluorescence intensity (MedFI) of streptavidin binding
of EGFP-positive cells are presented in a graph indicating ±SD of three independent transient expression experiments; ****p < 0.0001. (C) Negative control 293T (gray
population) and cTag8-expressing 293T cells co-expressing EGFP (cTag8 293T, red population) were first stained with streptavidin conjugated to APC, and samples were
analyzed by flow cytometry. Samples were then washed and incubated with 1 mM biotin for 1 hr at room temperature and analyzed by flow cytometry. Results are presented
as overlaid contour plots before (Streptavidin) and after (1 mM biotin) biotin addition.
www.moleculartherapy.orgStreptavidin Vector Purification Is Blocked by Biotin and
Influenced by cTag8 Expression Density
To demonstrate cTag8 speciﬁcity of capture, washed streptavidin
Dynabeads were incubated with either plain PBS or with PBS supple-
mented with an excess of 15 mM biotin for 1 hr at room temperature.
After PBS washing, NM and cTag8 LVs were incubated with pre-
treated beads under optimal conditions (see Figure S3 for optimiza-
tion of the surface area of streptavidin beads per infectious unit and
capture incubation time). After ﬂow-through separations, infectious
titers were determined for all fractions by infectivity assay (Figure 3B).
Dynabeads pre-incubated with PBS only resulted in a signiﬁcant
5-fold increase in the viral titer of captured cTag8 LVs, compared
to starting material, with 0.17 ± 0.02 of the titer remaining in ﬂow-
through. In contrast, pre-incubation of streptavidin Dynabeads
with 15 mM biotin blocked cTag8 LV binding, resulting in a lack of
capture, with 0.99 ± 0.2 of cTag8 LVs found in the ﬂow-through frac-
tion. Accordingly, a signiﬁcant statistical difference was observed
between viral titers of PBS- and biotin pre-incubated Dynabead frac-
tions with p # 0.0001, indicating that cTag8 LVs are occupying
biotin-binding sites on streptavidin. Next, we tested whether there
was a correlation between capture efﬁciency and epitope density onMolecular Theviral particles. To that end, cTag8 293T cells were sorted by ﬂow cy-
tometry into low, medium, and high cTag8-expressing cells (Fig-
ure S4). cTag8 LVs produced from these sorted populations, along
with negative control NM LVs, were subjected to streptavidin puriﬁ-
cation using optimized conditions, and viral titers of all fractions were
determined by infectivity assay (Figure 3C). There was a signiﬁcant
difference between viral titers of bead fractions and ﬂow-through
fractions produced from medium and high cTag8-expressing cells,
but not low cTag8-expressing cells. These results indicated that pas-
sive incorporation of cTag8 into virions is (as expected) proportional
to the density of cTag8 expression on the surface of the cells and that
there is a threshold of expression, below which cTag8 incorporation
onto viral particles was not sufﬁcient for complete viral particle cap-
ture by the beads.
cTag8-Based Purification Is Envelope Independent
As this puriﬁcation relies on the passive incorporation of cTag8 onto
viral particles, we next aimed to demonstrate that this process can
purify vectors regardless of pseudotyping envelope. For this purpose,
cTag8 LVs pseudotyped with either RDpro, MLV-ampho, or VSV-G
were produced frommedium cTag8-expressing 293T cells. Harvestedrapy: Methods & Clinical Development Vol. 11 December 2018 157
Figure 2. Generation of cTag8-Expressing 293T Cells for Modified Vector Production
(A) Both 293T (non-transduced) and 293T cells expressing cTag8 (cTag8 293T) by g-retroviral transduction with cTag8 co-expressed with EGFP were stained with
streptavidin-APC for cTag8 expression analysis by flow cytometry. (B) Surface expression analysis of cTag8 by immunofluorescence staining of cTag8 293T cells with
streptavidin-APC. Engineered cells were assessed for LV packaging capacity by the production of LVs from both 293T cells (non-modified, NM LVs) and cTag8 293T cells
(cTag8 LVs) in plain DMEM, pseudotyped with either RDpro, MLV-ampho, or VSV-G glycoproteins. (C) Viral supernatants were frozen, viral titers (infectious units (IU)/mL) of
stocks were determined by infectivity assay, and mean values are presented ± SD of triplicate determinations. (D) Sucrose-cushion-ultracentrifuge-purified VSV-G pseu-
dotyped NM LVs and cTag8 LVs were negatively stained and analyzed by transmission electron microscopy (TEM). Scale bars, 200 nm.
Molecular Therapy: Methods & Clinical Developmentvector supernatants were incubated with streptavidin beads for 1 hr at
room temperature, and infectious titers were determined for all frac-
tions (Figure 4). cTag8-modiﬁed vectors were successfully captured
by streptavidin beads, as indicated by increased viral titers of all
bead fractions, with increased viral recovery of 1.60 ± 0.21, 3.53 ±
0.55, and 2.22 ± 0.19 of total viral input, compared to neat fractions,
for RDpro, MLV-ampho, and VSV-G LVs, respectively (Figure 4).
These results demonstrated the independence of our puriﬁcation
methodology from viral pseudotyping.
Biotin Mediates Elution of Captured cTag8-Modified LVs
With a dissociation constant for cTag8-streptavidin binding in the
nanomolar range, the presence of biotin should outcompete captured
cTag8 LVs for streptavidin binding and, subsequently, allow the
desorption of cTag8 LVs. To conﬁrm this, optimal biotin concentra-
tion for efﬁcient vector elution was ﬁrst determined by incubating
vector bound to magnetic beads with Opti-MEM containing
decreasing concentrations of biotin from 15 mM to 15 fM in 100-
fold serial dilutions. A concentration of 500 mM biotin was deter-
mined as optimal for subsequent experiments (Figure S5). Next,
desorption efﬁciencies of captured cTag8 LVs were tested in the pres-
ence or absence of protein additives and in different media commonly
used for virus production. Accordingly, after the capture of cTag8158 Molecular Therapy: Methods & Clinical Development Vol. 11 DecemLVs by streptavidin magnetic beads (Figure S6A), fractions were
incubated with plain medium (X-VIVO 15, DMEM, or Opti-MEM)
or supplemented with 500 mM biotin or with 500 mM biotin and
0.5% BSA. The incubation was performed for 1 hr at room tempera-
ture without any volume reduction. Eluate fractions were collected
after magnetic bead immobilization, and viral recoveries were deter-
mined by infectivity assay (Figure S6B). The addition of BSA as an
excipient to biotin resulted in the highest overall yields, compared
to biotin only for all mediums used, with 67 ± 5.6%, 58 ± 8%, and
59 ± 9% using X-VIVO 15, DMEM, and Opti-MEM, respectively.
Interestingly, in the absence of BSA, X-VIVO 15 resulted in superior
elution recovery compared to DMEM and Opti-MEM, highlighting
its endogenous protein composition that seemed to aid higher yields.
These results indicated that our one-step puriﬁcation methodology
can be applied to various culturing media supplemented with biotin
and BSA, resulting inR60% elution recoveries of infectious LVs.
Eluted cTag8-Modified Vectors Are of High Purity
High vector purity is as important as infectious particle recovery and a
prerequisite for an effective downstream puriﬁcation vector process.
To demonstrate the efﬁciency of our puriﬁcation, captured cTag8
LVs were eluted in 50 reduced volume (compared to that of the
starting supernatant material) using Opti-MEM supplemented withber 2018
Figure 3. Streptavidin-Mediated Complete Capture of cTag8-Modified LVs
Transiently produced LVs from 293T and cTag8 293T cells, termed NMLVs and cTag8 LVs, respectively, were incubatedwith streptavidin magnetic beads. Dynabeadswere
immobilized by magnetic capture, and flow-through fractions were collected. Streptavidin Dynabeads were then washed 4 times with cold PBS and resuspended in cold
medium, in the same volume as starting viral supernatants. Viral titers (IU/mL) of all fractions: (1) crude (Neat), (2) re-suspended magnetic bead (Beads), and (3) post-capture
incubation flow-through (Flow-Through) fractions were determined by infectivity assay on 293T cells. (A) NM LVs and cTag8 LVs were produced in either serum-supple-
mented IMDM (serum) or serum-free DMEM (plain) medium. Viral supernatants were then subjected to capture methodology for 2 hr at 4C. (B) Streptavidin Dynabeads were
pre-treated either with plain or 15mM biotin-supplemented PBS for 1 hr at room temperature. After 3 washes with PBS, pre-treated beads were incubated with cTag8 LVs in
serum-free media for 1 hr at room temperature. (C) LVs were produced in serum-free media from low (L), medium (M), and high (H) cTag8-expressing 293T cells transiently.
Along with control NM LVs, all viral supernatants were incubated with streptavidin Dynabeads for 1 hr at room temperature. All values presented represent viral recovery of
each fraction compared to corresponding total vector input. Data are plotted ± SD of triplicate determinations. **p% 0.01; ***p% 0.001; ****p% 0.0001; ns, non-significant.
www.moleculartherapy.org500 mMbiotin and 0.5% BSA (Figure 4A). Eluted viral vectors resulted
in a 26-fold increase in viral titer (1.09 ± 0.04  106 IU/mL), which
represented 60% of the starting viral particles (Figures 5A and 5B).
Subsequently, to determine the purity achieved with this method,
eluted vectors were analyzed for process-related impurities. First,
double-stranded DNA (dsDNA) concentrations were determined
with the PicoGreen assay kit, which can detect down to 1 ng/mL nu-
cleic acids. As dsDNA does not speciﬁcally bind to streptavidin, the
majority of dsDNA from starting material (108 ng/mL) was detected
in the ﬂow-through fractions, whereas undetectable levels of dsDNA
were found in the concentrated eluate (Figure 5C). Taking the total
volume of both starting material and eluted LVs, our one-step puriﬁ-
cation led to the removal of >99.98% (>3-log) of the total dsDNA.
Second, host-cell protein (HCP) contamination was assessed in
biotin-displaced cTag8 LVs. HEK293 host cell proteins were quanti-
ﬁed in both starting supernatant and puriﬁed vectors using an
HEK293 HCP ELISA kit (Figure 5D). 1,468 ± 181 ng/mL HCP was
detected in starting neat supernatant, compared to 12 ± 4 ng/mL de-
tected in puriﬁed cTag8 LV eluate, eliminating 99.8 ± 0.04% of the to-
tal HCP (p = 0.0051). Therefore, our developed afﬁnity puriﬁcationMolecular Theresulted in a 2-log reduction of host cell DNA and protein impurities
in a one-step viral puriﬁcation process.
Scalability of Purification Using Streptavidin-Based Affinity
Chromatography
To determine the suitability of this puriﬁcation to process large vol-
umes of cTag8 LVs, we next tested viral capture in monolith-based
columns.We selected CIMac high-performance streptavidin columns
(BIA Separations). As this type of column has never been tested for
chromatographic puriﬁcation of LVs, a preliminary strategy using a
column with a column volume (CV) of 0.1 mL and streptavidin den-
sity of 2 mg/mm2 was established to attempt to capture and elute
cTag8 LVs by afﬁnity chromatography (Figure 6A). Subsequent to
priming the column, 500 CV of serum-free RDpro-pseudotyped
cTag8 LV was loaded onto the column, and ﬂow-through was
collected in 10-mL fractions. Next, 150 CV of X-VIVO 15-based
elution buffer containing a saturating concentration of 15 mM biotin,
supplemented with 0.5% BSA, was loaded into the column; and six
elution fractions of 15 CV (i.e., 1.5 mL) (E1–E6) were collected, fol-
lowed by a ﬁnal 75 CV fraction (E7). All collected fractions wererapy: Methods & Clinical Development Vol. 11 December 2018 159
Figure 4. Purification of cTag8-Modified LVs in an Envelope-Independent
Manner
Thawed NM LVs and cTag8 LVs pseudotyped with either RDpro, MLV-ampho, or
VSV-G glycoproteins were incubated with streptavidin Dynabeads for 1 hr at room
temperature. Dynabeads were immobilized by magnetic capture, and flow-through
fractions were collected. Streptavidin Dynabeads were then washed 4 times with
cold PBS and resuspended in cold medium in the same volume as starting viral
supernatants. Viral titers (international units per milliliter) of all fractions: (1) crude
(Neat), (2) re-suspended magnetic beads (Beads), and (3) post-capture incubation
flow-through (Flow-Through) fractions were determined by infectivity assay on 293T
cells. Data represent the viral recovery of each fraction compared to corresponding
total vector input and are plotted ± SD of triplicate determinations; **p % 0.01;
****p% 0.0001.
Molecular Therapy: Methods & Clinical Developmentthen assayed for viral titer by an infectivity assay (Figure 6B). The
loading of cTag8 LVs supernatant (4.58 ± 0.28  104 IU/mL, total
yield 2.29 x106 TU) onto the column resulted in good vector binding
to immobilized streptavidin, as indicated by the presence of only
9.11  104 total transducing units (TU) detected in all of the ﬁve
10 mL collected ﬂow-through fractions, which represented 4% of total
TU (Figure 6C). Moreover, washing the column did not displace any
bound LVs, indicating speciﬁc and high binding afﬁnity of cTag8 LVs
to the column. Furthermore, the loading of the elution buffer onto the
column resulted in the gradual desorption of cTag8 LVs from the col-
umn, with a clear eluted viral peak in E2 containing a concentrated
titer of 8.21 ± 0.3  104 IU/mL, representing an 1.8- ± 0.11-fold in-
crease compared to starting vector material. The elution of cTag8 LVs
continued in E3 with 4.40 ± 0.91  104 IU/mL and in E4 with 2.82 ±
0.71  104 IU/mL, which represented 96% and 61% of the starting
titer, respectively. Interestingly, in the last collected fractions of E5
to E7, cTag8 LV displacement continued in a stable manner, with
similar titers in all three fractions of 1.77  104 IU/mL, representing
38% of the input titer. Taking into consideration the volume of each
fraction, an overall yield of 20% was achieved in all elution fractions
by biotin displacement of cTag8 LVs in this preliminary afﬁnity chro-
matography run.
DISCUSSION
Here, we report a novel, one-step LV puriﬁcation methodology
achieved by the passive incorporation of a genetically encoded cyclical
biotin mimic onto viral particles, which allowed the capture of LVs
with reversible binding by biotin outcompetition, for both small-
and large-scale applications. To the best of our knowledge, this report160 Molecular Therapy: Methods & Clinical Development Vol. 11 Decemrepresents the ﬁrst use of a synthetic biotin-mimicking peptide for the
puriﬁcation of LVs.
The current downstream processing technologies for LV puriﬁca-
tion represent a major bottleneck for the advancement of these
vectors in both pre-clinical and clinical applications. The inefﬁ-
ciency of currently used methods is emphasized by the require-
ment of puriﬁcation schemes, which consist of at least 4 different
steps or technologies.5,14–17 These methods aim to either debulk
the surrounding supernatant from viral vectors (e.g., UF/DF and
SEC) or rely on the overall charge of viral particles for puriﬁcation
(e.g., AEX). Although AEX suffers from low speciﬁcity and co-
elution of negatively charged impurities, it is currently the most
widely applied puriﬁcation technology for both laboratory and
clinical scale LV puriﬁcation, with several commercial kits avail-
able, such as Merck Millipore’s Fast-Trap kit, ABM’s PuRetro
LV kit, Cell Biolabs’s ViraBind LV kit, and Sartorius’s Vivapure
LentiSELECT kit. However, desorption from AEX matrices re-
quires the use of harsh reagents; thus, efﬁcient elution comes at
the cost of the most important objective of any downstream pro-
cess, which is to maintain vector infectivity. Thus, all of these lim-
itations and the constraint in utilizing at least 4 technologies in
currently applied multi-step schemes are, in turn, translated into
the currently acceptable overall yield of 30% for clinical down-
stream processing of LVs, with published yields ranging between
20% and 40%.2,42
It is well recognized that the development of a speciﬁc puriﬁcation
strategy based on afﬁnity chromatography holds promising potential
to increase overall yield and in turn decrease the total cost of goods in
LV manufacturing, as fewer steps would be required. However, to
date afﬁnity puriﬁcation of LVs has had limited success, as vector
speciﬁcity has not yet been coupled with gentle desorption from afﬁn-
ity ligands. These two features are key in any viral puriﬁcationmethod
for its efﬁcacy in vector manufacturing, both technically and econom-
ically. Thus, the development of a cost-effective afﬁnity puriﬁcation
with gentle elution conditions, such as competitive elution, is highly
desirable for the widespread use of LVs in both clinical and research
applications. Accordingly, this work has addressed current limita-
tions in LV downstream processes by the establishment of a novel
one-step speciﬁc vector puriﬁcation, which selectively isolated
passively modiﬁed LVs followed by gentle desorption, resulting in
competitive overall yields with remarkably high levels of product
purity.
A precedent to this project was the metabolic desthiobiotinylation of
LVs with their subsequent puriﬁcation using monomeric avidin.43 As
desthiobiotin binds avidin at a lower afﬁnity than biotin,44 the loading
of 2 mM biotin onto the columns with adsorbed desthiobiotinylated
vectors resulted in the high recovery of 68% of the infectious virus.
However, this strategy has several limitations due to the relative
complexity of viral engineering, involving the co-expression of three
exogenous proteins in packaging cells. Moreover, the synthesis of des-
thiobiotin in these cells requires the addition of 7-DAPA into theber 2018
Figure 5. Biotin-Mediated Concentration and Purification of cTag8 LVs
LVs produced from cTag8 293T cells were incubated with streptavidin Dynabeads for 1 hr at room temperature. Dynabeads were then washed 4 times with PBS and
resuspended in plain DMEM and a fraction was collected. Subsequently, Dynabeads were magnetically immobilized and resuspended in Opti-MEM supplemented with
500 mM biotin and 0.5% BSA in 1/50th of the starting volume and incubated for 1 hr at room temperature. Post-magnetic immobilization of Dynabeads, concentrated eluted
LVs (eluate) were collected. (A) Viral titers (IU/mL) of starting (Neat), captured (Beads) and elution (Eluate) fractions were determined by infectivity assay, fromwhich (B) the total
transducing units (Total TU) in starting and eluted fractions were calculated. (C) Concentrations of dsDNA were quantified in collected viral fractions by PicoGreen analysis
(detection limit < 1 ng/mL). (D) Total immunoreactive HEK293 host cell proteins (HCPs) were detected in starting and eluted LV fractions. All values are presented ± SD of
three independent experiments; **p% 0.01.
www.moleculartherapy.orgculture, which may contain traces of biotin, rendering this strategy
ineffective for complete viral capture.
In our strategy, the cell surface expressing synthetic biotin mimic,
cTag8, was genetically engineered into packaging cells. This circum-
vents the need formetabolic conjugation while having the same advan-
tage as desthiobiotin allowing facile displacement with biotin. It should
also be noted that the nature of our vector modiﬁcation would also
incorporate the mimic onto non-virus-cell-derived vehicles produced
from cTag8-expressing packaging cells, such as exosomes, which in
turnwould lead to their co-puriﬁcation alongwith viral vectors. Never-
theless, as these particles share both size and charge to LVs, their co-pu-
riﬁcation using current technology for LV puriﬁcation is common.
Interestingly, the developed puriﬁcation presented in this study may
be of use for non-virus-cell-derived particle puriﬁcation.
The speciﬁcity of this afﬁnity-based isolation was shown to be inde-
pendent of viral envelope glycoproteins, demonstrating general viral
vector applications. Following the complete capture of cTag8-modi-
ﬁed LVs, biotin’s competitive binding to streptavidin routinely re-
sulted in overall yields of R60% from magnetic beads and 20%
from the preliminary chromatographic monolith-based puriﬁcation.
Greater recovery yields from the afﬁnity chromatography could be
achieved by further optimization of column desorption conditions.
Optimal elution recovery was achieved by the addition of BSA as
an excipient in the elution buffer. However, recombinant human
serum albumin could be used as a substitute, which does not require
characterization and removal from the ﬁnal vector product if in-
tended for clinical application.
Furthermore, the selectivity of our puriﬁcation was demonstrated
with the characterization of eluted LVs in terms of process-relatedMolecular Theimpurities. The selective capture of cTag8-expressing viral particles
followed by their elution in a biotin-dependent manner resulted in
a >3-log and a 2-log reduction in dsDNA (<1 ng/mL ﬁnal
concentration) and host-cell-derived protein (12 ng/mL ﬁnal con-
centration) contaminants, respectively. These reductions are com-
parable and competitive to reported values for both impurities in
ﬁnal LV product after its subjection to the multi-step puriﬁcation
schemes used, which in striking contrast, include benzonase treat-
ments as well as at least one chromatographic puriﬁcation step.
Thus, this methodology seems to result in superior impurity
removal in a one-step process compared to currently applied
multi-step schemes.
The integration of such a vector-speciﬁc puriﬁcation technique,
which combines high yield with high purity, would be highly advan-
tageous for the clinical manufacturing of LVs. The reduction of
current schemes, after vector clariﬁcation, to potentially just one af-
ﬁnity-based chromatographic puriﬁcation step would simultaneously
decrease the cost of processing and increase volume bioprocessing,
thus releasing the current bottleneck in LV manufacturing. The indi-
rect nature of cTag8modiﬁcation on viral particles effectively demon-
strates that our developed puriﬁcation may represent a universal
isolation technique for viral vectors produced either transiently or
from a stable packaging or producer cell line.
MATERIALS AND METHODS
Cell Culture
HEK293T/17 (ATCC, CRL-11268) cell line was cultured in IMDM
(Lonza) supplemented with 10% FCS (Biosera, FB 1001/500) and
2 mM GlutaMAX (GIBCO) at 37C with 5% CO2. 293T cells were
passaged 1:4–1:10 when cell density reached 75%–85% conﬂuence us-
ing trypsin-EDTA solution (Sigma).rapy: Methods & Clinical Development Vol. 11 December 2018 161
Figure 6. Affinity Chromatography Purification of cTag8 LVs Using Streptavidin Monolith Column
(A) Diagram of the CIMac streptavidin (0.1-mL) analytical column purification step process, with indicated collected fractions (5  10 mL flow-through fractions; 2  15 mL
wash fractions; 6 1.5mL [1 to 6], and 1 7.5mL [7] eluate fractions), which were assessed for their viral titers by infectivity assay. (B) Viral titers of collected fractions, and (C)
the yield of each fraction in terms of total transducing units (TU), which are represented as a percentage of starting input transducing units. Values are presented ± SD of
triplicate determinations for each fraction.
Molecular Therapy: Methods & Clinical DevelopmentViral Vector Production
Viral vector production was achieved by transiently transfecting 293T
cells in 100-mm plates using GeneJuice (Merck Millipore, 70967),
with a total of 12.5 mg DNA. g-retroviral vectors were produced by
triple transient transfection of 4.69 mg Peq-Pam plasmid (encoding
Moloney GagPol), 3.13 mg RDF plasmid (encoding RD114 envelope),
and 4.69 mg retroviral backbone SFG45 expressing the gene of interest.
Supernatants were collected 48 hr and 72 hr post-transfection and
frozen at 80C. LVs were generated by GeneJuice transfection of
cells with 5.42 mg pCMV-dR8.74 (encoding lentiviral GagPol),Titer

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!
 dilution factor2.92 mg envelope plasmid (pMD2.G, RDpro,40 or MLV-ampho-ex-
pressing plasmid, gifts from Dr. Yasu Takeuchi, University
College London), and 4.17 mg lentiviral backbone pCCL encoding
the gene of interest. Supernatants were collected 48 hr after
transfection and processed by centrifugation at 1,000  g for
10 min at 4C to remove cellular debris, followed by ultraﬁltration us-
ing Minisart NML 0.45-mm ﬁlters (Sartorius). Viral supernatants
were either kept on ice for 2 hr for further use or frozen at 80C
for storage.
Retroviral Modification of 293T Cells
Experiments were performed in 6-well plates (250,000 cells per well).
Culture media were replaced the day after seeding with g-retroviral
vector supernatant carrying cTag8 co-expressed with the EGFP
marker gene, in the presence of 5 mg/mL polybrene (Merck Milli-
pore). Transduced cells (cTag8 293T cells) were harvested 72 hr later
and recovered by culturing in serum-supplemented IMDM for two
passages before use as lentiviral packaging cells.162 Molecular Therapy: Methods & Clinical Development Vol. 11 DecemDetermination of LV Titer
Functional viral titers were determined by ﬂow cytometry analysis
(using a BD LSRFortessa X-20 cell analyzer) of transgene expression
in transduced 293T cells at different dilutions. Experiments were per-
formed in 24-well plates (50,000 cells per well). Serially diluted viral
supernatants (concentrated or neat un-concentrated) were added
onto seeded cells in the presence of 5 mg/mL polybrene. Transduction
efﬁciencies were determined 72 hr later, and transgene expressions
between 0.5% and 20% were used in the following equation to deter-
mine viral titer.Biotin-Mimetope-Mediated Purification of Modified LVs Using
Streptavidin Dynabeads
LVs produced from both 293T and cTag8 293T cells were either left
in supplemented IMDM or gently washed with PBS 24 hr post-
transfection and cultured in plain DMEM. Viral supernatants
were harvested 24 hr later, and after processing, fresh, frozen, or
thawed crude supernatants were incubated with Dynabeads MyOne
Streptavidin T1 (Thermo Fisher, 65601) magnetic beads (0.5 mg
beads per milliliter of LV supernatants) that were previously washed
with PBS 4, per the manufacturer’s protocol, and resuspended in
1 PBS. Capture conditions were incubated for 15 min to 2 hr at
4C or 37C, as stated per experiment, with gentle rotation. Tubes
were placed on a magnetic rack and left to stand for 1 min, followed
by the separation of the supernatant from the immobilized magnetic
beads (ﬂow-through fraction, 1 volume). Tubes were removed
from the magnetic rack, and beads were gently resuspended with
PBS and placed again on the magnetic rack for 1 min for bead
immobilization. This washing step was repeated 3 times, for a totalber 2018
www.moleculartherapy.orgof 4 washes, and beads were then resuspended in supplemented
IMDM or plain DMEM to collect a bead fraction (1 volume). Af-
ter resuspension for fraction collection, streptavidin beads were
magnetically immobilized and resuspended in one the following
elution buffers (1 volume): DMEM (GIBCO), Opti-MEM
(GIBCO), or X-VIVO 15 (Lonza), with biotin and/or BSA (as
mentioned per experiment), both supplied from Sigma-Aldrich.
Elution steps were incubated for 1 to 2 hr at 4C or room temper-
ature (as stated per experiment) with gentle rotation; subsequently,
tubes were placed on a magnetic rack, and eluates were collected af-
ter bead immobilization.
Determination of Streptavidin Dynabead Purification Efficiency
All fractions (neat supernatants, bead fractions, ﬂow-throughs, and
bead eluates) were titered on 293T cells by incubating fractions
with cells in the presence of 5 mg/mL polybrene to determine viral
titer. For the titration of the bead fractions, LVs bound to beads
were incubated with cells. To avoid the presence of beads during
the ﬂow cytometry assessment of transgene expression, all transduced
conditions were split 1:2–1:3 72 hr post-transduction to dilute out the
magnetic beads. 48 hr later, transduction efﬁciencies of the
EGFP transgene were determined by ﬂow cytometry using the BD
LSRFortessa X-20 cell analyzer.
Streptavidin Analytical Monolith Column Purification of
Modified LVs
Based on the manufacturer’s recommendation, the column was
placed in an upright position and connected to a peristaltic pump us-
ing connector tubes. The column ﬁtted was washed with 50 CVs of
PBS with a ﬂow rate of 1.5 mL/min. Subsequently, the column was
primed with 500 CVs of plain DMEM, which is equivalent to vec-
tor-containing media of viral supernatants. After the column was
washed with 50 CVs of PBS, 500 CVs (i.e., 50 mL) of serum-free
RDpro-pseudotyped cTag8 LV were loaded into the system at
1.5 mL/min, and ﬁve ﬂow-through fractions of 10 mL were collected.
The column was then washed twice with 300 CV with PBS, and wash
ﬂow-throughs were also collected. Next, an isocratic elution was per-
formed by loading 15 mL X-VIVO 15-based elution buffer, contain-
ing 15 mM biotin supplemented with 0.5% BSA, into the column,
which represented a third of the cTag8 LV total loaded volume for
the concentration of eluted vector. With a dead volume of 4 mL in
the tubing system and the fact that X-VIVO 15 is colored compared
to PBS, two fractions of 1.5 mL, termed E1 and E2, were collected, as
they represented the point of mixture between wash and elution solu-
tions. Four elution fractions of 1.5 mL were then collected (E3–E6),
followed by a ﬁnal 7.5-mL elution fraction (E7).
Immunofluorescence
cTag8 293T cells were cultured in 24-well plates overnight at 5  105
cells per well. Themediumwas removed, and cells were gently washed
with PBS. Cells were then ﬁxed with 4% paraformaldehyde in PBS for
20 min at room temperature and then gently washed 3 times with
PBS. To block non-speciﬁc binding, PBS + 0.1% BSA was added for
30 min. Streptavidin-APC (BioLegend) was then added in blockingMolecular Thesolution at 1:100 for 1 hr. Wells were washed 3 times with PBS after
staining removal. Nuclear staining was carried out using propidium
iodide (Thermo Fisher Scientiﬁc) in blocking solution at 1:3,000 for
5 min. Wells were washed 3 times with PBS and then imaged using
PBS ZEISS ﬂuorescence microscopy with the Colibri illumination
system.
Sucrose Cushion Purification
Processed LVs were gently layered on freshly prepared 20% sucrose in
50 mM sodium phosphate in ultracentrifuge tubes. Tubes were spun
at 23,000 rpm for 2 hr at 4C in a SW 32 Ti swinging-bucket rotor
(Beckman Coulter). Pellets were gently resuspended in Opti-MEM
and left on ice for 1 hr for optimal dissociation. Viral vectors were ali-
quoted and stored at 80C.
Electron Microscopy
Negative staining was performed by the sequential drop method;
brieﬂy, samples were adsorbed onto carbon-formvar electron micro-
scopy (EM) grids (Agar Scientiﬁc, Stansted, UK) for 1 min; then each
grid was placed sample side down on top of a 50-mL droplet of deion-
ized H2O for 30 s, followed by a 2-min staining on top of a 50-mL
droplet of 2% aqueous ammonium molydbate (pH 7.5) (Agar Scien-
tiﬁc). Excess stain was wicked off using Whatman Grade 1 ﬁlter pa-
per, and the grid was allowed to air dry. Grids were examined at
200 kV in a JEM-2100 TEM microscope (JEOL, Welwyn Garden
City, UK) at 10–60,000 magniﬁcation, and areas with the most
even stain levels were selected for image acquisition using a Gatan
Ultrascan 4000 charge-coupled device (CCD) camera (Gatan, Pleas-
anton, CA, USA).
Cell Sorting by Flow Cytometry
1 106 cTag8 293T cells were sorted using a BD FACSAria III sorter,
based on EGFP expression, into round-bottom ﬂuorescence-activated
cell sorting (FACS) tubes containing 0.5 mL 100% FCS supplemented
with Normocin at 100 mg/mL (Invivogen). Samples were then moved
into ﬂasks and incubated at 37C with 5% CO2. After two rounds of
cell division, recovered populations were assessed for sorting efﬁ-
ciency by ﬂow cytometry staining using a BD LSRFORTESSA X-20
cell analyzer.
DNA Quantification
Double-stranded DNA contamination was assessed in puriﬁed vec-
tors using the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen).
The manufacturers’ protocol was followed using a Thermo Scientiﬁc
Nunc F96 MicroWell black polystyrene plate. Absorbance was
measured using the Varioskan LUX multimode microplate reader
and analyzed using the SkanIt software.
HCP Quantification
Total HCP was measured by ELISA with the HEK293 HCP Kit
(Cygnus Technologies, F650). The manufacturers’ protocol was
followed with diluent buffer (Cygnus, I028-500). Absorbance was
measured using the Varioskan LUX multimode microplate reader
and analyzed using the SkanIt software.rapy: Methods & Clinical Development Vol. 11 December 2018 163
Molecular Therapy: Methods & Clinical DevelopmentStatistical Analysis
An unpaired two-tailed Student’s t test was used for comparison of
matched values with only two sets of data present. A two-way
ANOVA was used for comparison of groups with two variables pre-
sent across more than two sets of data. Generation of graphs and sta-
tistical analysis were performed using Prism 7.0 software.
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